THEMISMEDBSETHEMIS MEDICARE LTD.MediumNeutral
Announced Thu, 13 Aug · 15:48 IST

Q1 FY27 results, profit on share sale, Company Secretary change

Board & Shareholder Meetings View source PDFExplain this filing

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.1%1-day move
₹103.79
prior close
₹103.96
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.4+0.3-0.6+0.0+3.1+2.1+1.1-0.8+2.1+14.8+15.9+15.7
Up moveDown movePending
AI summary

Themis Medicare reported Q1 FY27 standalone revenue of Rs 8,695.69 lakhs, down from Rs 9,757.77 lakhs a year ago. Core operations posted a loss before exceptional items of Rs 5,694.46 lakhs, but a Rs 99.67 crore exceptional gain on sale of shares in Gujarat Themis Biosyn flipped it to a profit of Rs 2,855.34 lakhs (EPS Rs 3.12). Board accepted Mr Nagraj Mogaveera's resignation as Interim Company Secretary and appointed Mr Suresh Savaliya (23 years experience) as the new Company Secretary and Compliance Officer.

Likely market impact

Core business still loss-making; reported profit is driven by a one-time share sale gain. New Company Secretary appointment is a routine governance change.